Nexans Acquires Republic Wire To Establish U.S. Manufacturing Platform In Low-Voltage Cable Market

Nexans, a Paris-based global electrification company, has signed an agreement to acquire 100% of Republic Wire, a family-owned American manufacturer of low-voltage copper and aluminum wire products headquartered in Cincinnati, Ohio. The deal, valued at approximately 680 million euros with a potential earn-out of up to 43 million euros, establishes Nexans’ first significant manufacturing and distribution platform in the United States and complements its recent acquisition of Electro Cables in Canada.

Founded in 1982, Republic Wire serves electrical wholesale distributors, utilities, and municipalities across the United States and Canada. The company operates a 32,500-square-meter manufacturing facility and a newly completed 30,000-square-meter warehouse and distribution center, employing more than 200 people. A recently completed expansion program is expected to be fully online by the end of 2026, increasing production capacity by approximately 30%. Republic Wire generated approximately 520 million euros in revenue over the twelve months through February 2026.

The U.S. low-voltage cable segment is estimated at approximately 12 billion euros and is driven by sustained demand across residential, commercial, and data center construction. Nexans projects approximately 23 million euros in run-rate synergies over three years, driven by commercial cross-selling, manufacturing technology deployment, and purchasing scale.

The transaction is expected to be immediately earnings-per-share accretive before synergies and is anticipated to close in the early third quarter of 2026, subject to regulatory approval. Republic Wire’s current management team, led by Ron and Jeremy Rosenbeck, will remain in place.

KEY QUOTES:

“The acquisition of Republic Wire marks a transformative moment in Nexans’ journey to become a reference pure player in electrification. The United States represents the single largest growth opportunity in low- and medium-voltage cable. Republic Wire gives us the expanded platform, the customer relationships and the operational credibility we need to compete in this highly dynamic market.”

Julien Hueber, Chief Executive Officer, Nexans

“Republic Wire has always been more than a business to our family — it is a legacy built on hard work, loyalty, and a deep responsibility to our customers and the people who chose to build their careers here. In Nexans, I found a partner who shares those values, not just a buyer.”

Ron Rosenbeck, CEO, Republic Wire

“The acquisition of Republic Wire represents an important strategic milestone, meaningfully strengthening our position in the North American market. As a highly respected brand with a proven track record of exceptional quality and customer centricity, Republic Wire brings deep market relationships and an extensive commercial network.”

Tim King, Managing Director North America, Nexans

Source link

Telix Advances Radiopharma Platform With Key Trials And US Manufacturing Shift

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

• Telix Pharmaceuticals (ASX:TLX) has resubmitted its NDA for TLX101-Px, a PET imaging agent for brain cancer.

• The company reported that Part 1 of the global Phase 3 ProstACT study for TLX591-Tx in prostate cancer met primary safety and tolerability objectives.

• Telix expanded its U.S. manufacturing footprint with new cyclotron installations to support in-house radioisotope production and supply resilience.

At a share price of A$12.75, Telix Pharmaceuticals (ASX:TLX) sits against a mixed recent track record, with the stock up 12.9% over the past week and 43.6% over the past month, but showing a 54.4% decline over the past year. Over a longer period, the share price return sits at 87.2% over three years and 183.3% over five years. This provides context to the current interest around the company’s pipeline and manufacturing updates.

For investors watching Telix, the NDA resubmission for TLX101-Px, the Phase 3 safety readout for TLX591-Tx and the new U.S. cyclotron capacity are central elements of the current story. The way these clinical and operational milestones progress, and whether they lead to regulatory outcomes and commercial activity, is likely to influence sentiment on ASX:TLX.

Stay updated on the most important news stories for Telix Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Telix Pharmaceuticals.

ASX:TLX Earnings & Revenue Growth as at Mar 2026

3 things going right for Telix Pharmaceuticals that this headline doesn’t cover.

The NDA resubmission for TLX101-Px, the positive Part 1 readout from the ProstACT Phase 3 trial for TLX591-Tx, and the U.S. cyclotron rollout all point to Telix working on three parts of its model at once: diagnostics, therapeutics and infrastructure. TLX101-Px targets recurrent or progressive glioma, an area where the FDA currently has no approved targeted amino acid PET agent, so regulatory progress here would speak directly to Telix’s neuro-oncology focus and its companion diagnostic strategy alongside TLX101-Tx. On the prostate cancer side, acceptable safety and tolerability for TLX591-Tx in combination with standard therapies gives Telix more footing in a space where companies such as Novartis and Bayer are active with radioligand and oncology treatments. The cyclotron agreement in the U.S. moves Telix further into vertically integrated production, which can reduce dependence on external isotope suppliers compared with peers that lean more on contract manufacturers. For investors, the thread tying these updates together is execution risk: more assets and infrastructure can deepen the opportunity, but they also raise the bar on Telix’s ability to manage capital, regulatory interactions and complex supply chains over time.

• The NDA resubmission for TLX101-Px and progress in ProstACT Global align with the narrative of building a multiproduct, multi-region radiopharmaceutical platform across urologic and neuro-oncology indications.

• The extra data and statistical work needed for TLX101-Px, and the ongoing regulatory interactions for TLX591-Tx, highlight that clinical and regulatory pathways can be slower or more resource intensive than simple catalyst timelines might imply.

• The cyclotron rollout into RLS and TMS sites was anticipated in the narrative, but contract specific details such as the IBA agreement and ARTMS technology may not be fully captured in earlier assumptions about manufacturing integration and supply reliability.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Telix Pharmaceuticals to help decide what it’s worth to you.

• ⚠️ Heavier investment into clinical programs like ProstACT Global and into cyclotron infrastructure could keep reported earnings and margins under pressure if revenue does not keep pace.

• ⚠️ Regulatory processes for TLX101-Px and TLX591-Tx, together with existing regulatory scrutiny around prostate cancer disclosures, add uncertainty around timing and ultimate outcomes.

• 🎁 Progress across both diagnostic and therapeutic candidates, along with manufacturing integration, supports the idea of Telix evolving into a broader radiopharmaceutical platform rather than a single product story.

• 🎁 U.S. cyclotron capacity and in-house radioisotope production can improve supply chain resilience and may support more consistent availability of products versus competitors that rely mainly on third party isotope suppliers.

Investors should watch for the FDA’s response to the TLX101-Px NDA resubmission, including any further data requests, and updates on the transition of ProstACT Global into its larger Part 2 expansion and U.S. IND amendment. Progress on installing and qualifying the new U.S. cyclotrons, and how quickly they begin supplying Telix products at scale, will be key to understanding execution on the vertical integration plan. It is also worth tracking how Telix positions its prostate and brain cancer offerings in relation to radiopharma peers, and whether management provides clearer guidance on capital spend, margins and timelines as these programs and assets move through their next stages.

To ensure you’re always in the loop on how the latest news impacts the investment narrative for Telix Pharmaceuticals, head to the community page for Telix Pharmaceuticals to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include TLX.AX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Source link

Morph Systems, a defense industry and U.S. manufacturing data integration platform developer, announ..

Defense & U.S. Manufacturing Data Platform
Palantir Foundry Technology Utilization

사진 확대 A case of Morph Systems’ ontology construction that can identify relationships between unstructured data [Morph Systems]

Morph Systems, a defense industry and U.S. manufacturing data integration platform developer, announced on the 20th that it has attracted pre-seed investment from Mashup Ventures and 500 Global.

Morph Systems is an enterprise AI company that designs supply chain data and workflow for defense and U.S. manufacturing companies that are pushing for utilization advancement after the introduction of Palantir. Establish an ontology model that systematically defines data relationships according to the customer’s work context, and design data flows so that ERP (company resource management), logistics, settlement, and operation data can lead to actual decision-making and execution.

In addition, for organizations in the early stages of Palantir introduction, data and work structure design is also being carried out considering future expansion. Customers can have a data processing structure and a high-performance computing environment that can operate stably even if the supply chain expands. The technological excellence of these morph systems is advantageous not only at the manufacturing site, but also in the military and defense industry environment that requires large-scale material movement and strict traceability.

CEO Park Min-gyu, a graduate of Seoul National University’s Department of Aerospace Engineering, has published a number of international academic papers in the field of reinforcement learning, served as an AI researcher at the Korea Military Academy, and conducted defense and public AI projects. While working on a Palantir Foundry-based consulting project, he discovered the demand for data integration in the manufacturing and defense industries and decided to start a business. Co-founder Koo Ha-rim is a graduate of the Department of Mechanical Engineering at the National University of Singapore and has two startup experiences and is in charge of data integration and AI system implementation directly in the field.

Morph Systems expects 40% of its sales to come from U.S. customers since its first year, and to expand to more than 80% this year. Recently, in recognition of the excellence of data integration technology that can handle large-scale supply chains stably, it was selected for the TIPS program organized by the Ministry of SMEs and Startups and secured up to 500 million won in R&D funds. The selection of this tip was made on the recommendation of Mashup Ventures.

“After attracting this investment, we plan to implement a large-scale ontology-based computational and decision-making operation system centered on the U.S. market,” said Park Min-gyu, CEO of Morph Systems. “The ultimate goal is to expand to Neo-Cloud infrastructure and software layers optimized for specific industries and workloads based on our experience in operating field-oriented AI systems.”

Lee Seung-guk, a Mashup Ventures partner who led the investment, said, “The demand for data integration and decision-making automation is increasing rapidly in the process of re-industrialization and supply chain reorganization in the United States. Morph Systems is a team that solves core problems in the manufacturing and defense industry based on Palantir Foundry-based data integration technology and field-oriented experience, and it is expected to grow quickly in the U.S. market.”

Source link